For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

The NCCN and ESMO guidelines recommend testing for BRAF in advanced NSCLC1,2

Biomarker identification can aid therapy selection for patients with NSCLC

 Infographic: 3 of 10 patients with NSCLC have actionable mutations.

Guidelines recommend testing for these biomarkers in NSCLC: BRAF, MET, HER2, ALK rearrangement, EGFR mutation, RET, and ROS1.

  • Upfront biomarker testing can help determine actionable targets1,2
  • Up to 2% of patients with NSCLC have BRAF V6004-7

Employ broad biomarker testing to identify patients with an actionable mutation3

ESMO, European Society for Medical Oncology; NCCN, National Comprehensive Cancer Network.

References: 1NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.1.2018. © National Comprehensive Cancer Network, Inc. Accessed January 9, 20182Besse B, Adjei A, Baas P, et al; and Panel Members. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014;25(8):1475-1484. 3Lovly C, Horn L, Pao W. Molecular profiling of lung cancer. My Cancer Genome website. March 28, 2016. Accessed March 13, 2017. 4Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non–small-cell lung cancer harboring BRAF mutations. Clin Oncol. 2011;29(26):3574-3579. 5Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013;19(16):4532-4540. 6Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. Clin Oncol. 2011;29(15):2046-2051. 7Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998-2006.